Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cybin ( (TSE:CYBN) ) has shared an announcement.
Cybin announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, where its Chief Business Officer, George Tziras, will engage in a fireside chat. This participation underscores Cybin’s commitment to advancing mental healthcare solutions and highlights its strategic positioning in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a Phase 3 clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare through innovative drug discovery platforms and delivery systems. The company is developing novel treatments for mental health conditions, including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, with operations in Canada, the United States, the United Kingdom, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
See more data about CYBN stock on TipRanks’ Stock Analysis page.